Biotechnology

Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 6, 2022 9:00 AM

SAN DIEGO, CA / ACCESSWIRE / September 6, 2022 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that Gerry Proehl, Dermata's Chairman of the Board, President, and Chief Executive Officer will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference being held...

Read more

CB Scientific, Inc. Announces FDA 510(k) Submission of Enhanced myCam Cardiac Event Monitor

September 6, 2022 6:00 AM

Updated product to include significant operating improvements and material design advances over the current offering ESCONDIDO, CA / ACCESSWIRE / September 6, 2022 / CB Scientific. Inc.(OTCQB:CBSC) ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products and services, today announced that it has completed the regulatory testing phase of its latest myCam cardiac event monitor...

Read more

BioInvent Completes the Planned Dose-Escalation in Phase 1/2a trial of BI-1808 in Advanced Malignancies

September 6, 2022 2:20 AM

LUND, SWEDEN / ACCESSWIRE / September 6, 2022 / BioInvent International (STO:BINV) BI-1808 shown to be safe and well tolerated with no serious adverse events observed Given the positive safety and tolerability profile, higher doses will be explored Three disease stabilizations observed during the escalation process Cohort to explore potential synergistic activity in combination with Keytruda® is now enrolling patients Lund, Sweden - September 6,...

Read more

Lexaria Welcomes Dr. Catherine Turkel to its Board of Directors

September 2, 2022 9:15 AM

KELOWNA, BC / ACCESSWIRE / September 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that Catherine Turkel, PharmD, PhD has joined the board of directors of Lexaria Bioscience Corp. "It is a pleasure to join the Lexaria Board of Directors at such an exciting time in the Company's evolution," said Dr. Turkel. "I look forward to...

Read more

Announcement from Biovica International AB's annual general meeting

August 31, 2022 10:20 AM

UPPSALA, SE / ACCESSWIRE / August 31, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) The annual general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 31 August 2022 and the following resolutions were passed by the meeting. ADOPTION OF THE INCOME STATEMENT AND BALANCE SHEET The annual general meeting resolved to adopt Biovica's income statement and balance sheet as well as the...

Read more

Lexaria Receives New Patent in Mexico

August 31, 2022 9:05 AM

KELOWNA, BC / ACCESSWIRE / August 31, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce its continued accumulation of international patent recognition with the receipt of its 27th worldwide patent granted in Mexico under registration #390001. This patent is from Lexaria's third patent family, "Stable Ready-to-Drink Beverage Compositions...

Read more

Endoscopic Sleeve Gastroplasty (ESG) Procedure Featured as a "Top 10" Paper at the IFSO 2022 World Congress in Miami

August 31, 2022 7:30 AM

Patients undergoing ESG achieved 24% total body weight loss in a bariatric surgery practice in a community setting. AUSTIN, TX / ACCESSWIRE / August 31, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced that the endoscopic sleeve gastroplasty (ESG) procedure was featured in a 2022 Top 10 Paper at the International Federation for...

Read more

Q1 Interim Report May-July 2022/2023 - DiviTum(R)TKa Approved for Launch in the US

August 31, 2022 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / August 31, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) SEK t Q1 22/23 Q1 21/22 May-April 21/22 Net sales 545 381 2,045 Operating profit (loss) -20,662 -12,238 -60,101 Profit (loss) for the period -21,004 -12,225 -60,003 Earnings per share, after dilution -0.74 -0.43 -2.11 Significant events during the first quarter · Results with DiviTum®TKa at ASCO · ...

Read more

Mymetics and PCI Biotech Sign a Preclinical Research Collaboration

August 31, 2022 2:00 AM

EPALINGES, SWITZERLAND / ACCESSWIRE / August 31, 2022 / Mymetics Corporation (OTCQB:MYMX) a pioneer in the research and development of virosome based vaccines and immunotherapies against infectious and life disabling diseases, and PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharmaceutical company, have entered into a preclinical research collaboration with the aim to explore technological synergies for the possible enhancement of...

Read more

ITOCO Introduces It's Soil Rescue Program ("SRP") to Africa

August 30, 2022 6:57 AM

TORONTO, ON / ACCESSWIRE / August 30, 2022 / ITOCO INC. (OTC PINK:ITMC), is pleased to announce that through its Portuguese subsidiary, Colorful Euphoria, Lda, it has commenced the introduction of its Soil Rescue Program, "SRP" into the Republic of Nigeria. ITOCO's representatives have completed a 7-day visit to the Republic of Nigeria where they presented the ITOCO "SRP" to several government agencies and departments including the Ministry of...

Read more

Organicell Regenerative Medicine, Inc. Closes $5.5 Million Funding Round

August 26, 2022 4:30 PM

MIAMI, FL / ACCESSWIRE / August 26, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focused on the development of innovative regenerative medicine and biological therapeutics, has closed its previously announced $4.0 million capital raise at $0.02 and corporate restructuring transaction. Organicell also closed on an additional $1.5 million of funding at $0.04 per share from two...

Read more

BioInvent International AB: Interim Report January-June 2022

August 25, 2022 2:20 AM

LUND, SWEDEN / ACCESSWIRE / August 25, 2022 / BioInvent International (STO:BINV) "The second quarter 2022 was eventful for BioInvent, delivering a deal with the US biotech company Exelixis, positive progress in our clinical portfolio and strengthened organizational leadership. All this was followed by a successful financing in July. We now have four drug candidates advancing through five clinical studies and in several cases, we have reported...

Read more

Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase

August 24, 2022 4:05 PM

SAN DIEGO, CA / ACCESSWIRE / August 24, 2022 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that Dermata will participate in the Gilmartin Group Emerging Growth Company Showcase, being held on August 31, 2022. Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata, will...

Read more

Pressure BioSciences Secures Pivotal Cosmeceuticals Partnership for UST Platform With Dr. Denese SkinScience, 20-Year Leader With Over $0.5 Billion in QVC Sales

August 24, 2022 8:15 AM

Collaborative UST-Driven Research and Development Agreement Announced With Dr. Adrienne Denese (QVC Icon, Skincare Visionary, Anti-Aging Pioneer, & Creator of Award-Winning SkinScience Labs) Targets Revolutionary Nanoemulsion-Driven Performance in New, Proprietary Skincare Products SOUTH EASTON, MA / ACCESSWIRE / August 24, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly...

Read more

Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS

August 24, 2022 8:00 AM

BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the presentation of preclinical data for PRS-400, an inhaled Jagged-1 Anticalin protein the Company is developing for the treatment of muco-obstructive lung...

Read more

Ensysce Biosciences Announces Completion of Clinical Portion of Human Abuse Potential Trial PF614-103

August 23, 2022 8:05 AM

Completion of Clinical Portion Represents Critical Milestone Towards Commercialization Nasal Opioid Abuse Being Explored for PF614 Data From Trial Expected in September 2022 SAN DIEGO, CA / ACCESSWIRE / August 23, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today...

Read more

CB Scientific, Inc. (CBSC) and Shenzhen Pump Medical Co., Ltd. Announce Cooperative Manufacturing Agreement for Chinese Market

August 23, 2022 6:00 AM

Shenzhen Pump Medical Co. Ltd. to formally become the recognized manufacturer of record for CBSC's myCam device, cloud-based software, and smartphone app in China. SHENZHEN, CHINA and ESCONDIDO, CA / ACCESSWIRE / August 23, 2022 / CB Scientific. Inc. (OTCQB:CBSC) ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products and services, is pleased to announce that it has entered into...

Read more

BrainChip and Edge Impulse Host Webinar

August 22, 2022 5:30 PM

Bringing development of BrainChip Akida Neuromorphic models to all using Edge Impulse LAGUNA HILLS, CA / ACCESSWIRE / August 22, 2022 / BrainChip Holdings Ltd (ASX:BRN)(OTCQX:BRCHF)(ADR:BCHPY), the world's first commercial producer of neuromorphic AI IP, and Edge Impulse, the leading development platform for machine learning (ML) on edge devices, are hosting the webinar "Bringing development of BrainChip Akida Neuromorphic models to all using...

Read more

Hemogenyx Pharmaceuticals PLC Announces Appointment of Director of Quality

August 22, 2022 2:00 AM

Quality System Expert Joins Hemogenyx Pharmaceuticals as Director of Quality LONDON, UK / ACCESSWIRE / August 22, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces the appointment of Mr Stuart Tinch as Director of Quality. Stuart brings over seven years of Good Manufacturing Practice ("GMP") expertise to Hemogenyx Pharmaceuticals. He will be...

Read more

Black Bird Biotech Signs Distribution Agreement with Chicago-based Distributor of Luxury Spa Products for its Grizzly Creek Naturals(TM) CBD Product Line

August 18, 2022 7:30 AM

FLOWER MOUND, TX / ACCESSWIRE / August 18, 2022 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer and distributor of plant-based MiteXstreamTM biopesticide, announced that it has entered into a distribution agreement for its Grizzly Creek NaturalsTM CBD product line with Chicago-based Beyond Das Skin, a national distributor of luxury spa products. During its over 40 years of distribution operations, Beyond Das Skin has established a...

Read more